Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Company validates DNA methylation test as predictor of breast cancer recurrence
June 16th, 2005
Epigenomics, AG, (ECX) revealed data confirming that its DNA methylation markers are closely correlated with disease recurrence and prediction of therapy response in early breast cancer. Specific DNA methylation markers, including PITX2, will be incorporated into a test that will provide physicians with clinically relevant information that may spare approximately half of estrogen-dependent, node-negative breast cancer patients from going through the discomfort and side effects of chemotherapy. Currently, combined chemotherapy and endocrine therapy with drugs such as Tamoxifen is recommended as the treatment of choice for most breast cancer patients to prevent the...
Source: Women's Health Weekly (2005-06-16)
|
